RINGPU(SZ:300119) Xin Lang Cai Jing·2025-09-03 05:49Core Viewpoint - The stock of Reap Bio has experienced fluctuations, with a recent decline in price and significant trading activity, indicating potential investor concerns and market dynamics [1][2]. Company Overview - Reap Bio, established on August 2, 2001, and listed on September 17, 2010, is located in the Tianjin Free Trade Zone and specializes in veterinary biological products, chemical drugs, biological agents, and animal health products [2]. - The company's main revenue sources include poultry biological products (35.04%), formulations and raw materials (33.24%), pet supply chain (20.63%), livestock biological products (6.86%), and others [2]. Financial Performance - For the first half of 2025, Reap Bio reported a revenue of 1.708 billion yuan, representing a year-on-year growth of 55.37%, and a net profit attributable to shareholders of 257 million yuan, up 61.19% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 1.371 billion yuan in dividends, with 462 million yuan distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and Guotai CSI Livestock Breeding ETF, with notable changes in their holdings [3].